[CAS NO. 112529-15-4] Pioglitazone HCl

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [112529-15-4]

Catalog

SLK-S2046

Brand

Selleck

CAS

112529-15-4

DESCRIPTION [112529-15-4]

Overview

MDL	MFCD04975446
Molecular Weight	392.9
Molecular Formula	C19H20N2O3S.HCl
SMILES	C(C1C(=O)NC(=O)S1)C2=CC=C(OCCC3=CC=C(CC)C=N3)C=C2.Cl

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.5452 mL	12.7259 mL	25.4518 mL
5 mM	0.5090 mL	2.5452 mL	5.0904 mL
10 mM	0.2545 mL	1.2726 mL	2.5452 mL
50 mM	0.0509 mL	0.2545 mL	0.5090 mL

Description

Pioglitazone HCl (AD-4833, U-72107E) is an inhibitor of and enzymes. Pioglitazone HCl inhibits CYP2C8, CYP3A4 and CYP2C9 with Ki of 1.7 μM, 11.8 μM and 32.1 μM, respectively. Pioglitazone HCl is also a selective agonist with EC50 of 0.93 μM and 0.99 μM for human PPARγ and mouse PPARγ, respectively. Pioglitazone HCl inhibits mitochondrial iron uptake, lipid peroxidation, and subsequent .

Targets

In vitro

Pioglitazone inhibits LPS-induced iNOS expression and NO generation, and inhibition of iNOS is sufficient to protect dopaminergic neurons against LPS insult. Pioglitazone protects dopaminergic neurons against LPS insult at least via inhibiting iNOS expression and NO generation, which is potentially mediated via inhibition of p38 MAPK activity. Pioglitazone inhibits LPS-induced phosphorylation of p38 MAPK.

References

[1] Xing B, et al. J Neuroinflammation,?008, 5, 4.
[2] Sugiyama Y, et al. Arzneimittelforschung,?990, 40(3), 263-267.
[3] Burkhard Schütz, et al. J Neurosci,?005, 25(34), 7805-7812.
[4] Ikeda H, et al. Arzneimittelforschung,?990, 40(2 Pt 1), 156-162.
[5] Kondo T, et al. Arzneimittelforschung,?996, 46(6), 594-600.
[6] Kenji Kuwabara, et al. J Pharmacol Exp Ther . 2004 Jun;309(3):970-7.
[7] Jasminder Sahi, et al. Drug Metab Dispos . 2003 Apr;31(4):439-46.
[8] Hua Yuan, et al. Biochem Biophys Res Commun . 2016 Sep 16;478(2):838-44.

Synonyms

2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, hydrochloride (1:1)

2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride, (±)-

2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, monohydrochloride

U 72107A

Pioglitazone hydrochloride

AD 4833

Actos

5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione hydrochloride

Poze

Piomed

Glutazone

Sepioglin

Paglitaz

Glidipion

Glustin